Drugs / GM1
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04976127 | Dec 2021 → Aug 2025 | Parkinson disease | InnoMedica Schweiz AG | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07585565 | May 2026 → Mar 2028 expected | Parkinson disease | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06431971 | Aug 2024 → Nov 2025 | Parkinson disease | InnoMedica Schweiz AG | Unknown | No outcome recorded |
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT06994507 | Aug 2025 → Sep 2026 overdue | chemotherapy-induced neuropathy | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT02251977 | Sep 2014 → Sep 2017 | colorectal cancer, neutropenia | Yuhong Li | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GM1 | “Talineuren consists of the pharmacologically active ingredient GM1, associated with a proprietary lipid formulation assembled as liposomes.” NCT04976127 ↗4“Talineuren is a liposomal formulation containing GM1 (monosialotetrahexosylganglioside) as the pharmacological active substance.” NCT06431971 ↗ |
| Known as | GM1 Ganglioside | “Talineuren is a liposomal formulation of the GM1 Ganglioside for intravenous administration” NCT04976127 ↗ |
| Route | Intravenous | “randomly assigned to intravenous GM1 or a placebo” PMID 31724334 ↗ Nov 2019 |